×

Get the Prostate Cancer Patient Guide as a digital download or free mailed copy.

Click here.

2015-YI-SAUL-PRICEMAN

Saul Priceman

Supplementing a patient’s immune response by engineering their killer white blood cells (CAR T-cells) to recognize, bind to, and eliminate the tumor is a new and transformational area of cancer...Read More

2015-YI-SEAN-MCGUIRE

Sean McGuire

New hormonal treatments for prostate cancer such as Xtandi® and Zytiga® are effective, but patients invariably become resistant to these medications. Dr. Sean McGuire’s innovative research is evaluating potential therapeutic...Read More

2015-YI-RAVI-MADAN

Ravi Madan

Immune checkpoint inhibitors “take the brakes” off a patient immune response, resulting in immune elimination of the cancer. Patients with melanoma, renal, bladder, lymphoma and lung cancers have been successfully...Read More

2015-YI-ZHENFEI-LI

Zhenfei Li

While most men with prostate cancer initially respond well to androgen deprivation therapies (ADT) such as Zytiga®, some do not, and patients inevitably develop resistance to treatment. Recent research has...Read More

john-k-lee

John Kyung Lee

A highly aggressive subtype of treatment-resistant prostate cancer has been increasingly diagnosed in men who have suffered from the disease and were treated with androgen deprivation therapy. Small cell neuroendocrine...Read More

2015-YI-VISHAL-KOTHARI

Vishal Kothari

New therapeutic targets and prognostic biomarkers for treatment-resistance prostate cancer (CRPC) would greatly improve outlook and decrease mortality rates for men with advanced forms of this disease. Recent research has...Read More

Kim_Won

Won Kim

The emergence of treatment-resistant prostate cancer (CRPC) is an inevitable outcome for men treated with androgen receptor (AR) targeted therapies. At present, the biology of prostate cancer treatment resistance is...Read More

2015-YI-JOSEPH-IPPOLITO

Joseph Ippolito

Metabolic oxidative phosphorylation (OXPHOS) is a biochemical process that may lead to therapy resistance and tumor recurrence in men with prostate cancer. Characterizing the metabolism of treatment-resistant prostate cancer (CRPC)...Read More

Howard Scher google

Howard Scher

Cell signaling in cancer causes uncontrolled cell growth and many clinical properties of cancer, such as metastases. Two major pathways of cell signaling in prostate cancer are initiated through a...Read More

151714_hargrove_lab005

Amanda Hargrove

Long noncoding RNAs (lncRNAs) play a critical role in cell development by activating other molecules in charge of shaping gene expression. Recent research suggests that lncRNAs may be the most...Read More